Aurobindo Pharma Ltd

Aurobindo Pharma Ltd

₹ 1,241 -0.17%
21 Jun - close price
About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Key Points

Leading Pharmaceutical company [1]
Aurobindo Pharma is India’s second-largest pharma company & Largest generics company in the US (by Rx dispensed). It is also the largest generic company in the US and is amongst the top 10 generic companies in seven out of 11 countries in Europe.[2]The Company is among the top 5 listed pharmaceutical companies in India by FY22 revenues [3]

  • Market Cap 72,721 Cr.
  • Current Price 1,241
  • High / Low 1,292 / 696
  • Stock P/E 22.2
  • Book Value 509
  • Dividend Yield 0.36 %
  • ROCE 14.2 %
  • ROE 11.6 %
  • Face Value 1.00

Pros

Cons

  • The company has delivered a poor sales growth of 8.19% over past five years.
  • Company has a low return on equity of 10.3% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
6,002 5,702 5,942 6,002 5,809 6,236 5,739 6,407 6,473 6,851 7,219 7,352 7,580
4,735 4,502 4,766 4,993 4,839 5,303 4,950 5,453 5,477 5,702 5,846 5,753 5,920
Operating Profit 1,266 1,200 1,176 1,009 970 933 790 954 996 1,149 1,373 1,599 1,660
OPM % 21% 21% 20% 17% 17% 15% 14% 15% 15% 17% 19% 22% 22%
79 110 97 100 -114 41 57 93 135 47 188 163 14
Interest 18 13 10 16 9 15 25 45 56 57 68 76 89
Depreciation 266 280 294 299 254 280 298 321 346 327 418 423 354
Profit before tax 1,061 1,018 968 794 594 679 523 680 730 812 1,076 1,262 1,230
Tax % 24% 24% 28% 24% 3% 23% 22% 28% 31% 30% 30% 26% 26%
801 770 697 604 576 520 410 491 506 570 752 940 907
EPS in Rs 13.68 13.14 11.90 10.32 9.84 8.88 6.99 8.38 8.64 9.74 12.92 15.98 15.51
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
5,842 8,089 12,103 13,772 14,910 16,463 19,564 23,099 24,775 23,455 24,855 29,002
4,965 5,951 9,524 10,579 11,469 12,691 15,612 18,249 19,497 19,060 21,148 23,176
Operating Profit 877 2,137 2,579 3,193 3,441 3,772 3,952 4,849 5,278 4,396 3,707 5,826
OPM % 15% 26% 21% 23% 23% 23% 20% 21% 21% 19% 15% 20%
12 18 81 200 115 105 70 166 3,195 152 291 366
Interest 267 310 160 257 67 78 263 305 74 49 140 290
Depreciation 249 313 333 392 428 558 668 967 1,055 1,127 1,245 1,522
Profit before tax 374 1,533 2,168 2,744 3,061 3,241 3,091 3,743 7,344 3,373 2,612 4,380
Tax % 22% 24% 28% 26% 25% 25% 24% 24% 27% 22% 26% 28%
291 1,169 1,571 2,024 2,301 2,423 2,364 2,844 5,334 2,647 1,928 3,169
EPS in Rs 5.05 20.12 26.98 34.61 39.29 41.36 40.36 48.56 91.05 45.20 32.90 54.15
Dividend Payout % 15% 7% 8% 7% 6% 6% 6% 6% 4% 20% 23% 3%
Compounded Sales Growth
10 Years: 14%
5 Years: 8%
3 Years: 5%
TTM: 17%
Compounded Profit Growth
10 Years: 11%
5 Years: 6%
3 Years: -1%
TTM: 71%
Stock Price CAGR
10 Years: 13%
5 Years: 16%
3 Years: 10%
1 Year: 78%
Return on Equity
10 Years: 16%
5 Years: 13%
3 Years: 10%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 29 29 29 59 59 59 59 59 59 59 59 59
Reserves 2,577 3,721 5,127 7,229 9,313 11,622 13,832 16,766 21,871 24,517 26,781 29,784
3,435 3,769 4,451 5,041 3,364 4,770 6,967 5,826 5,339 2,851 5,286 6,648
1,232 1,970 3,303 3,568 3,464 4,492 5,414 6,113 6,147 6,211 7,379 8,581
Total Liabilities 7,273 9,490 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 39,505 45,072
2,639 2,722 3,706 4,180 4,834 6,521 8,475 9,396 9,374 10,532 11,024 15,622
CWIP 219 310 420 848 1,458 1,583 1,668 1,986 3,062 3,747 5,390 2,739
Investments 22 20 20 123 246 312 360 555 591 997 543 372
4,393 6,439 8,765 10,745 9,662 12,527 15,768 16,827 20,390 18,362 22,549 26,338
Total Assets 7,273 9,490 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 39,505 45,072

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
275 646 1,237 1,420 3,279 1,955 1,651 4,381 3,329 5,016 2,387 2,435
-246 -819 -1,017 -1,446 -1,787 -1,927 -2,904 -1,563 597 -3,211 -3,978 -4,256
108 118 93 365 -1,915 864 1,919 -1,947 -1,365 -2,969 1,814 800
Net Cash Flow 137 -55 313 340 -424 892 666 871 2,561 -1,164 223 -1,021

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 100 119 107 122 68 68 64 68 52 62 66 61
Inventory Days 235 240 239 240 246 317 304 289 333 272 275 284
Days Payable 118 137 136 146 122 128 107 97 103 97 125 129
Cash Conversion Cycle 217 222 210 217 191 257 260 260 282 237 216 216
Working Capital Days 171 162 126 141 122 139 148 120 124 120 120 126
ROCE % 11% 27% 27% 27% 25% 23% 18% 19% 18% 13% 9%

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
51.83% 51.83% 51.83% 51.83% 51.83% 51.84% 51.84% 51.84% 51.84% 51.84% 51.84% 51.84%
23.70% 21.71% 21.37% 20.83% 20.71% 21.41% 22.31% 23.03% 24.12% 22.45% 20.72% 18.01%
14.66% 15.52% 16.49% 17.47% 17.30% 16.56% 14.90% 15.09% 15.73% 18.29% 20.60% 23.28%
9.80% 10.93% 10.31% 9.86% 10.15% 10.20% 10.96% 10.06% 8.31% 7.43% 6.85% 6.87%
No. of Shareholders 2,43,3153,29,9403,41,5683,38,6393,59,6843,58,4593,69,8283,43,6172,93,2142,59,6382,41,9442,44,575

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls